An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
Drugs that selectively bind to and activate beta-adrenergic receptors.
Analogs and derivatives of atropine.
A group of methane-based halogenated hydrocarbons containing one or more fluorine and chlorine atoms.
A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.
A beta-2 selective adrenergic antagonist. It is used primarily in animal and tissue experiments to characterize BETA-2 ANDRENERGIC RECEPTORS.
Compressed gases or vapors in a container which, upon release of pressure and expansion through a valve, carry another substance from the container. They are used for cosmetics, household cleaners, and so on. Examples are BUTANES; CARBON DIOXIDE; FLUOROCARBONS; NITROGEN; and PROPANE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.
A long-acting beta-2-adrenergic receptor agonist.
A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-2 receptors are more sensitive to EPINEPHRINE than to NOREPINEPHRINE and have a high affinity for the agonist TERBUTALINE. They are widespread, with clinically important roles in SKELETAL MUSCLE; LIVER; and vascular, bronchial, gastrointestinal, and genitourinary SMOOTH MUSCLE.
AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives.
Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents.
Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.

Facilitatory beta2-adrenoceptors on cholinergic and adrenergic nerve endings of the guinea pig trachea. (1/134)

Using electrical field stimulation of epithelium-denuded intact guinea pig tracheal tube preparations, we studied the presence and role of prejunctional beta2-adrenoceptors by measuring evoked endogenous acetylcholine (ACh) and norepinephrine (NE) release directly. Analysis of ACh and NE was through two HPLC systems with electrochemical detection. Electrical field stimulation (150 mA, 0.8 ms, 16 Hz, 5 min, biphasic pulses) released 29.1 +/- 2.5 pmol ACh/g tissue and 70.2 +/- 6.2 pmol NE/g tissue. Preincubation for 15 min with the selective beta2-adrenoceptor agonist fenoterol (1 microM) increased both ACh and NE overflow to 178 +/- 28 (P < 0.01) and 165 +/- 12% (P < 0.01), respectively, of control values, increases that were abolished completely by the selective beta2-adrenoceptor antagonist ICI-118551 (1 microM). Further experiments with increasing fenoterol concentrations (0.1-100 microM) and different preincubation periods (1, 5, and 15 min) showed a strong and concentration-dependent facilitation of NE release, with maximum response levels decreasing (from nearly 5-fold to only 2.5-fold of control value) with increasing agonist contact time. In contrast, sensitivity of facilitatory beta2-adrenoceptors on cholinergic nerves to fenoterol gradually increased when the incubation period was prolonged; in addition, a bell-shaped concentration-response relationship was found at 15 min of preincubation. Fenoterol concentration-response relationships (15-min agonist preincubation) in the presence of atropine and yohimbine (1 microM each) were similar in the case of NE release, but in the case of ACh release, the bell shape was lost. The results indicate a differential capacity and response time profile of facilitatory prejunctional beta2-adrenoceptors on adrenergic and cholinergic nerve terminals in the guinea pig trachea and suggest that the receptors on adrenergic nerves are more susceptible to desensitization.  (+info)

Spontaneous labour at term is associated with fetal monocyte activation. (2/134)

The aetiology of both term and preterm labour remains incompletely understood. Maternal infectious diseases as well as intra-uterine infections were shown to be a well established cause of uncontrollable preterm delivery, indicating that inflammatory reactions, regulated by maternal immunecompetent cells, are implicated in labour-promoting mechanisms. To investigate the possibility that the activation of the fetal immune system may be involved in labour induction, we examined cytokine production patterns of different cord blood cell populations obtained from neonates after spontaneous onset of normal term labour and vaginal delivery (n = 25), vaginal delivery but induced term labour (n = 17), and preterm delivery because of uncontrollable labour (n = 27, 20 patients received corticoid treatment for fetal lung maturation), in comparison with cells obtained from neonates after elective term caesarean delivery in the absence of labour (n = 15). Our results demonstrate that spontaneous term labour, but not induced term labour, was associated with significantly increased IL-6 production by myelomonocytic cell populations. Preterm delivery due to uncontrollable labour with resistance to tocolysis was not associated with increased IL-6 production by fetal myelomonocytic cells. Two-colour flow cytometry combined with intracellular cytokine staining was used to identify fetal monocytes as sources of labour-associated IL-6 release at term. We did not find any activation of cord blood T cells in association with spontaneous term or uncontrollable preterm labour. Therefore, fetal T cell responses may not cause monocyte activation. Our results suggest that increased release of IL-6 from fetal monocytes is involved in mechanisms promoting normal term, but not preterm labour, and that mechanisms inducing term and preterm labour are completely different.  (+info)

beta 2-agonist-induced inhibition of neutrophil chemotaxis is not associated with modification of LFA-1 and Mac-1 expression or with impairment of polymorphonuclear leukocyte antibacterial activity. (3/134)

Patients with chronic obstructive lung disorders often show increased susceptibility to airway infections. As beta 2-adrenoceptor agonists, in addition to reversing the contractile response of bronchial smooth muscles, may inhibit a variety of inflammatory and immuno-effector cell functions, it is possible that these drugs interfere with host defence mechanisms. The present study was designed to test in vitro whether fenoterol, a short-acting beta 2-adrenoceptor agonist, could modify human blood neutrophil recruitment and antimicrobial activity. Pre-exposure to fenoterol significantly reduced neutrophil migration towards the complement component C5a, at concentrations ranging from 10(-7) M to 10(-5) M, or towards lipopolysaccharide, at a concentration of 10(-5) M (P < 0.05, each comparison). In contrast, the drug (10(-8)-10(-5) M) did not significantly modify the increased expression of lymphocyte function-associated antigen (LFA-1, i.e. CD11a/CD18) the macrophage antigen-1 (Mac-1, i.e. CD11b/CD18) induced by N-formylmethionylleucylphenylalanine (fMLP) (P > 0.05, each comparison). Finally, incubation of neutrophils with fenoterol (10(-8)-10(-5) M) did not significantly influence phagocytosis or intracellular killing of bacteria (Staphylococcus aureus) or H2O2 release induced by tetradecanoyl-phorbol-acetate (P > 0.1 for each comparison). These results suggest that short-acting beta 2-adrenoceptor agonists, such as fenoterol, are able partially to reduce neutrophil recruitment in the airways without interfering with the processes involved in phagocytic activity against bacteria.  (+info)

Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system. (4/134)

AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II. METHODS: In an open, parallel, randomized study healthy volunteers received i.v. either placebo (electrolyte solution), fenoterol or fenoterol in combination with an oral dose of the AT1-receptor antagonist losartan. RESULTS: Compared with placebo treatment AUCEPO(0,24 h) was significantly increased after fenoterol application by 48% whereas no increase in the group receiving fenoterol and losartan could be detected. The rise of PRA was statistically significant under fenoterol and fenoterol plus lorsartan. CONCLUSIONS: Stimulation of EPO production during fenoterol infusion appears to be angiotensin II-mediated. Thus, angiotensin II may be considered as one important physiological modulator of EPO production in humans.  (+info)

Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway calibre. (5/134)

Airway hyperresponsiveness (AHR), in which airway inflammation has been reported to be a key factor, is an important component of asthma. However the precise role of inflammation in AHR is still unclear. In this report, airway inflammatory changes were assessed using hypertonic saline-induced sputum examination and exhaled nitric oxide analysis, and the relation between AHR to methacholine, airway calibre forced expiratory volume in one second (FEV1) and airway inflammatory indices examined. Furthermore, the changes in these variables were also examined by means of 8 weeks' open uncontrolled inhaled steroid administration (800 microg x beclomethasone x day(-1)). Asthmatic subjects had higher eosinophil counts and bradykinin concentration in induced sputum and higher exhaled NO levels, and showed AHR to methacholine. Baseline AHR significantly correlated with FEV1 but not with indices of inflammation in sputum or exhaled air. Steroid inhalation therapy was associated with a reduction in eosinophil and bradykinin concentration in sputum and NO levels in exhaled air and an improvement in FEV1 and AHR. The changes in FEV1 and AHR were significantly related to changes in markers in sputum and exhaled air (p<0.01 for each). These results suggest that baseline airway hyperresponsiveness can be predicted from the airway calibre but not from inflammatory parameters in sputum or exhaled air. In contrast, the reversible component of airway hyperresponsiveness appeared to be associated with the reduction in airway inflammation.  (+info)

Up-regulation of airway smooth muscle histamine H(1) receptor mRNA, protein, and function by beta(2)-adrenoceptor activation. (6/134)

Histamine, released from activated mast cells, causes bronchoconstriction mediated by H(1) receptors, whereas beta(2)-agonists are widely used for the relief of bronchoconstriction. In this study, we examined the effects of the beta(2)-adrenoceptor agonist, fenoterol, on the expression of H(1) receptors at the mRNA and protein levels, and functional responses. Incubation of bovine tracheal smooth muscle with fenoterol (10(-7) M) for 2 h increased H(1) receptor mRNA (maximum approximately 190%). The number of H(1) receptors was increased after 12 and 18 h without any change in binding affinity. In the contraction experiments, the concentration-response curves for histamine-induced contraction were shifted significantly to the left after 18-h exposure to fenoterol, consistent with the increase in receptor number. The fenoterol-induced increase in H(1) receptor mRNA was concentration-dependent and was abolished by propranolol and ICI 118551, but not by CGP 20712A, indicating that fenoterol acts via beta(2)-adrenoceptors. These effects were mimicked by other cAMP-elevating agents forskolin and prostaglandin E(2), and by the stable cAMP analog 8-bromo-cAMP. Cycloheximide alone produced superinduction of H(1) receptor mRNA and augmented the fenoterol-induced increase in H(1) receptor mRNA. Fenoterol increased both the stability and the transcription rate of H(1) receptor mRNA. Pretreatment with dexamethasone did not prevent fenoterol-induced up-regulation of H(1) receptor mRNA. Thus, fenoterol increases the expression of airway smooth muscle H(1) receptors via activation of the cAMP system through increased gene transcription and mRNA stability. This mechanism may be involved in the adverse responses encountered with the clinical use of short-acting beta(2)-agonists.  (+info)

Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. (7/134)

The objective of this study was to compare the long-term safety of a fixed combination of fenoterol hydrobromide (50 microg) and ipratropium bromide (20 microg) delivered using a metered dose inhaler (MDI) formulated with a non-chlorinated propellant, hydrofluoroalkanel34a (HFA-MDI), with delivery using the conventional chlorofluorocarbon propellant (CFC-MDI, Berodual/Bronchodual). The study was designed according to Safety Assessment of Marketed Medicines (SAMM) guidelines, to reflect as far as possible the use of MDls under normal prescribing conditions. Two thousand and twenty-seven patients with chronic airways obstruction (CAO) were enrolled from 99 centres in France, 95 centres in Germany and 24 centres in Italy. Following a 2-week run-in period, patients were randomized on a 2:1 basis (1,348 patients to HFA-MDI, 679 patients to CFC-MDI) to receive a flexible dose regimen of the combination (2 puffs, 2-4 times a day, as prescribed by the investigator) during a 12-week open label phase. The overall incidence of adverse events was comparable between both groups. In addition, the incidence of respiratory side effects was also similar, with CAO exacerbations or bronchitis the most frequently recorded events. The safety profile of the HFA formulation was comparable to those of the marketed CFC-MDIs used in Germany and France/Italy. No clinically significant differences were detected between HFA134a or CFC driven inhalers on the switch from CFC- to HFA-MDI (2 weeks before randomisation versus 2 weeks after randomization). There was a trend for taste complaints to be reported more frequently by patients in the HFA-MDI group (0.7% before randomization versus 3.4% after randomization). This, however, was an expected finding as the HFA134a formulation does have a different taste to the CFC formulation. No difference between formulations was observed in the incidences of coughing or paradoxical bronchospasm. The incidence of falls in FEV1 >15% within 15 min following inhalation at each of the clinic visits was 1.2% for both CFC- and HFA-MDIs. In conclusion, administration of a fenoterol/ipratropium bromide combination via hydrofluoroalkane-metered dose inhaler is as safe as delivery by the currently available chlorofluorocarbon-metered dose inhaler, in an extended population of patients with CAO under normal prescribing conditions.  (+info)

Effects of fenoterol and ipratropium on respiratory resistance of asthmatics after tracheal intubation. (8/134)

We have studied the effects of a beta-agonist, fenoterol, and a cholinergic antagonist, ipratropium, on post-intubation total respiratory system resistance (Rrs) in asthmatics who developed increased Rrs after tracheal intubation. Sixteen stable asthmatics in whom Rrs increased after intubation were allocated randomly to receive either 10 puffs of fenoterol (group F) or 10 puffs of ipratropium (group IB) via a metered dose inhaler 5 min after intubation. Anaesthesia was induced and maintained with propofol i.v. Rrs was recorded before treatment and again 5, 15 and 30 min after treatment. Rrs decreased significantly from pretreatment values by mean 53 (SD 8)%, 53 (7)% and 58 (6)% at 5, 15 and 30 min, respectively, in group F, but declined by only 12 (6)%, 15 (4)% and 17 (5)% in group IB. At all times after treatment, patients in the fenoterol group had significantly lower Rrs values than those in the ipratropium group. We conclude that increased Rrs after tracheal intubation in asthmatics can be reduced effectively by treatment with fenoterol. A secondary finding of our study was that even after induction of anaesthesia with propofol, patients with a history of asthma may develop high Rrs.  (+info)

Fenoterol is a short-acting β2-adrenergic receptor agonist, which is a type of medication used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles in the airways and increasing the flow of air into the lungs, making it easier to breathe.

Fenoterol is available in various forms, including inhalation solution, nebulizer solution, and dry powder inhaler. It is usually used as a rescue medication to relieve sudden symptoms or during an asthma attack. Like other short-acting β2-agonists, fenoterol has a rapid onset of action but its effects may wear off quickly, typically within 4-6 hours.

It is important to note that the use of fenoterol has been associated with an increased risk of severe asthma exacerbations and cardiovascular events, such as irregular heartbeat and high blood pressure. Therefore, it should be used with caution and only under the supervision of a healthcare professional.

Adrenergic beta-agonists are a class of medications that bind to and activate beta-adrenergic receptors, which are found in various tissues throughout the body. These receptors are part of the sympathetic nervous system and mediate the effects of the neurotransmitter norepinephrine (also called noradrenaline) and the hormone epinephrine (also called adrenaline).

When beta-agonists bind to these receptors, they stimulate a range of physiological responses, including relaxation of smooth muscle in the airways, increased heart rate and contractility, and increased metabolic rate. As a result, adrenergic beta-agonists are often used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, as they can help to dilate the airways and improve breathing.

There are several different types of beta-agonists, including short-acting and long-acting formulations. Short-acting beta-agonists (SABAs) are typically used for quick relief of symptoms, while long-acting beta-agonists (LABAs) are used for more sustained symptom control. Examples of adrenergic beta-agonists include albuterol (also known as salbutamol), terbutaline, formoterol, and salmeterol.

It's worth noting that while adrenergic beta-agonists can be very effective in treating respiratory conditions, they can also have side effects, particularly if used in high doses or for prolonged periods of time. These may include tremors, anxiety, palpitations, and increased blood pressure. As with any medication, it's important to use adrenergic beta-agonists only as directed by a healthcare professional.

Atropine derivatives are a class of drugs that are chemically related to atropine, an alkaloid found in the nightshade family of plants. These drugs have anticholinergic properties, which means they block the action of the neurotransmitter acetylcholine in the body.

Atropine derivatives can be used for a variety of medical purposes, including:

1. Treating motion sickness and vertigo
2. Dilating the pupils during eye examinations
3. Reducing saliva production during surgical procedures
4. Treating certain types of poisoning, such as organophosphate or nerve gas poisoning
5. Managing symptoms of some neurological disorders, such as Parkinson's disease and myasthenia gravis

Some examples of atropine derivatives include hyoscyamine, scopolamine, and ipratropium. These drugs can have side effects, including dry mouth, blurred vision, constipation, difficulty urinating, and rapid heartbeat. They should be used with caution and under the supervision of a healthcare provider.

Chlorofluorocarbons (CFCs) and methane are both greenhouse gases that contribute to global warming and climate change. However, they are distinct substances with different chemical structures and sources.

Chlorofluorocarbons (CFCs) are synthetic compounds made up of carbon, chlorine, and fluorine atoms. They were commonly used in refrigerants, aerosol sprays, and foam blowing agents until they were phased out due to their harmful effects on the ozone layer. CFCs have high global warming potential, meaning that they trap heat in the atmosphere many times more effectively than carbon dioxide.

Methane, on the other hand, is a naturally occurring gas made up of one carbon atom and four hydrogen atoms (CH4). It is produced by the decomposition of organic matter, such as in landfills, wetlands, and the digestive tracts of animals like cattle. Methane is also released during the extraction and transportation of fossil fuels like coal, oil, and natural gas. While methane has a shorter lifespan in the atmosphere than CFCs, it is an even more potent greenhouse gas, trapping heat at a rate 25 times greater than carbon dioxide over a 100-year period.

Therefore, while both CFCs and methane are harmful to the climate, they are distinct substances with different sources and impacts.

Ipratropium is an anticholinergic bronchodilator medication that is often used to treat respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. It works by blocking the action of acetylcholine, a chemical messenger in the body that causes muscles around the airways to tighten and narrow. By preventing this effect, ipratropium helps to relax the muscles around the airways, making it easier to breathe.

Ipratropium is available in several forms, including an aerosol spray, nebulizer solution, and dry powder inhaler. It is typically used in combination with other respiratory medications, such as beta-agonists or corticosteroids, to provide more effective relief of symptoms. Common side effects of ipratropium include dry mouth, throat irritation, and headache.

Butoxamine is a pharmaceutical drug that acts as an antagonist or blocker for β2-adrenergic receptors. These receptors are found in various tissues throughout the body and play a role in mediating the effects of catecholamines such as adrenaline and noradrenaline.

Butoxamine is primarily used in research settings to study the functions of β2-adrenergic receptors and their signaling pathways. It has been used to investigate the role of these receptors in various physiological processes, including airway smooth muscle relaxation, lipolysis, and insulin secretion.

It is important to note that Butoxamine is not approved for use in humans as a therapeutic agent, and its use is restricted to research purposes only.

Aerosol propellants are substances used to expel aerosolized particles from a container. They are typically gases that are stored under pressure in a container and, when the container is opened or activated, the gas expands and forces the contents out through a small opening. The most commonly used aerosol propellants are hydrocarbons such as butane and propane, although fluorinated hydrocarbons such as difluoroethane and tetrafluoroethane are also used. Aerosol propellants can be found in various products including medical inhalers, cosmetics, and food products. It is important to handle aerosol propellants with care, as they can be flammable or harmful if inhaled or ingested.

Adrenergic beta-2 receptor agonists are a class of medications that bind to and stimulate beta-2 adrenergic receptors, which are found in various tissues throughout the body, including the lungs, blood vessels, and skeletal muscles. These receptors are part of the sympathetic nervous system and play a role in regulating various physiological processes such as heart rate, blood pressure, and airway diameter.

When beta-2 receptor agonists bind to these receptors, they cause bronchodilation (opening of the airways), relaxation of smooth muscle, and increased heart rate and force of contraction. These effects make them useful in the treatment of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and premature labor.

Examples of adrenergic beta-2 receptor agonists include albuterol, terbutaline, salmeterol, and formoterol. These medications can be administered by inhalation, oral administration, or injection, depending on the specific drug and the condition being treated.

It's important to note that while adrenergic beta-2 receptor agonists are generally safe and effective when used as directed, they can have side effects such as tremors, anxiety, palpitations, and headaches. In addition, long-term use of some beta-2 agonists has been associated with increased risk of severe asthma exacerbations and even death in some cases. Therefore, it's important to use these medications only as directed by a healthcare provider and to report any concerning symptoms promptly.

Bupranolol is a beta-blocker medication that is primarily used to treat high blood pressure, angina (chest pain), and certain types of irregular heartbeats. It works by blocking the action of certain natural substances in your body, such as epinephrine, that affect the heart and blood vessels. This helps to reduce heart rate, lower blood pressure, and improve blood flow, which can help prevent heart attacks and strokes.

Bupranolol may also be used for other purposes, such as preventing migraines or treating anxiety disorders. It is available in immediate-release and extended-release tablets, and the dosage may vary depending on the specific condition being treated. As with any medication, bupranolol can have side effects, including dizziness, fatigue, and gastrointestinal symptoms. It is important to follow your doctor's instructions carefully when taking this medication and to report any unusual or bothersome side effects promptly.

Procaterol is not a medication that has been approved by the US Food and Drug Administration (FDA) for use in the United States. However, it is a medication that is available in some other countries as a bronchodilator, which is a type of medication that is used to open up the airways in the lungs and make it easier to breathe.

Procaterol belongs to a class of medications called long-acting beta-agonists (LABAs). LABAs work by relaxing the muscles in the airways and increasing the size of the airways, which makes it easier for air to flow in and out of the lungs. Procaterol is often used to prevent symptoms of chronic obstructive pulmonary disease (COPD), such as shortness of breath and coughing.

It's important to note that procaterol has been associated with an increased risk of asthma-related deaths, so it should only be used under the close supervision of a healthcare professional and should not be used in people with asthma who are not also using a corticosteroid inhaler.

Albuterol is a medication that is used to treat bronchospasm, or narrowing of the airways in the lungs, in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is a short-acting beta-2 agonist, which means it works by relaxing the muscles around the airways, making it easier to breathe. Albuterol is available in several forms, including an inhaler, nebulizer solution, and syrup, and it is typically used as needed to relieve symptoms of bronchospasm. It may also be used before exercise to prevent bronchospasm caused by physical activity.

The medical definition of Albuterol is: "A short-acting beta-2 adrenergic agonist used to treat bronchospasm in conditions such as asthma and COPD. It works by relaxing the muscles around the airways, making it easier to breathe."

Adrenergic receptors are a type of G protein-coupled receptor that bind and respond to catecholamines, such as epinephrine (adrenaline) and norepinephrine (noradrenaline). Beta-2 adrenergic receptors (β2-ARs) are a subtype of adrenergic receptors that are widely distributed throughout the body, particularly in the lungs, heart, blood vessels, gastrointestinal tract, and skeletal muscle.

When β2-ARs are activated by catecholamines, they trigger a range of physiological responses, including relaxation of smooth muscle, increased heart rate and contractility, bronchodilation, and inhibition of insulin secretion. These effects are mediated through the activation of intracellular signaling pathways involving G proteins and second messengers such as cyclic AMP (cAMP).

β2-ARs have been a major focus of drug development for various medical conditions, including asthma, chronic obstructive pulmonary disease (COPD), heart failure, hypertension, and anxiety disorders. Agonists of β2-ARs, such as albuterol and salmeterol, are commonly used to treat asthma and COPD by relaxing bronchial smooth muscle and reducing airway obstruction. Antagonists of β2-ARs, such as propranolol, are used to treat hypertension, angina, and heart failure by blocking the effects of catecholamines on the heart and blood vessels.

Ethanolamines are a class of organic compounds that contain an amino group (-NH2) and a hydroxyl group (-OH) attached to a carbon atom. They are derivatives of ammonia (NH3) in which one or two hydrogen atoms have been replaced by a ethanol group (-CH2CH2OH).

The most common ethanolamines are:

* Monethanolamine (MEA), also called 2-aminoethanol, with the formula HOCH2CH2NH2.
* Diethanolamine (DEA), also called 2,2'-iminobisethanol, with the formula HOCH2CH2NHCH2CH2OH.
* Triethanolamine (TEA), also called 2,2',2''-nitrilotrisethanol, with the formula N(CH2CH2OH)3.

Ethanolamines are used in a wide range of industrial and consumer products, including as solvents, emulsifiers, detergents, pharmaceuticals, and personal care products. They also have applications as intermediates in the synthesis of other chemicals. In the body, ethanolamines play important roles in various biological processes, such as neurotransmission and cell signaling.

Aerosols are defined in the medical field as suspensions of fine solid or liquid particles in a gas. In the context of public health and medicine, aerosols often refer to particles that can remain suspended in air for long periods of time and can be inhaled. They can contain various substances, such as viruses, bacteria, fungi, or chemicals, and can play a role in the transmission of respiratory infections or other health effects.

For example, when an infected person coughs or sneezes, they may produce respiratory droplets that can contain viruses like influenza or SARS-CoV-2 (the virus that causes COVID-19). Some of these droplets can evaporate quickly and leave behind smaller particles called aerosols, which can remain suspended in the air for hours and potentially be inhaled by others. This is one way that respiratory viruses can spread between people in close proximity to each other.

Aerosols can also be generated through medical procedures such as bronchoscopy, suctioning, or nebulizer treatments, which can produce aerosols containing bacteria, viruses, or other particles that may pose an infection risk to healthcare workers or other patients. Therefore, appropriate personal protective equipment (PPE) and airborne precautions are often necessary to reduce the risk of transmission in these settings.

Nebulizer: A nebulizer is a medical device that delivers medication in the form of a mist to the respiratory system. It is often used for people who have difficulty inhaling medication through traditional inhalers, such as young children or individuals with severe respiratory conditions. The medication is placed in the nebulizer cup and then converted into a fine mist by the machine. This allows the user to breathe in the medication directly through a mouthpiece or mask.

Vaporizer: A vaporizer, on the other hand, is a device that heats up a liquid, often water or essential oils, to produce steam or vapor. While some people use vaporizers for therapeutic purposes, such as to help relieve congestion or cough, it is important to note that vaporizers are not considered medical devices and their effectiveness for these purposes is not well-established.

It's worth noting that nebulizers and vaporizers are different from each other in terms of their purpose and usage. Nebulizers are used specifically for delivering medication, while vaporizers are used to produce steam or vapor, often for non-medical purposes.

Bronchodilators are medications that relax and widen the airways (bronchioles) in the lungs, making it easier to breathe. They work by relaxing the smooth muscle around the airways, which allows them to dilate or open up. This results in improved airflow and reduced symptoms of bronchoconstriction, such as wheezing, coughing, and shortness of breath.

Bronchodilators can be classified into two main types: short-acting and long-acting. Short-acting bronchodilators are used for quick relief of symptoms and last for 4 to 6 hours, while long-acting bronchodilators are used for maintenance therapy and provide symptom relief for 12 hours or more.

Examples of bronchodilator agents include:

* Short-acting beta-agonists (SABAs) such as albuterol, levalbuterol, and pirbuterol
* Long-acting beta-agonists (LABAs) such as salmeterol, formoterol, and indacaterol
* Anticholinergics such as ipratropium, tiotropium, and aclidinium
* Combination bronchodilators that contain both a LABA and an anticholinergic, such as umeclidinium/vilanterol and glycopyrrolate/formoterol.

"Inhalation administration" is a medical term that refers to the method of delivering medications or therapeutic agents directly into the lungs by inhaling them through the airways. This route of administration is commonly used for treating respiratory conditions such as asthma, COPD (chronic obstructive pulmonary disease), and cystic fibrosis.

Inhalation administration can be achieved using various devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft-mist inhalers. Each device has its unique mechanism of delivering the medication into the lungs, but they all aim to provide a high concentration of the drug directly to the site of action while minimizing systemic exposure and side effects.

The advantages of inhalation administration include rapid onset of action, increased local drug concentration, reduced systemic side effects, and improved patient compliance due to the ease of use and non-invasive nature of the delivery method. However, proper technique and device usage are crucial for effective therapy, as incorrect usage may result in suboptimal drug deposition and therapeutic outcomes.

Fenoterol has more cardiovascular toxicity than isoprenaline or salbutamol. Fenoterol was widely used in New Zealand in the ... "Berotec Inhalation Solution (Fenoterol HBr)". RxMed.com. Retrieved 2018-06-11. Svedmyr N (1985-05-06). "Fenoterol: A Beta2- ... "Fenoterol Hydrobromide Drug Information, Professional". Drugs.com. 1996-01-01. Retrieved 2018-06-11. "Fenoterol - Drug ... Fenoterol is produced and sold by Boehringer Ingelheim as Berotec N and in combination with ipratropium as Berodual N. It was ...
Minette compared 6-mg and 12-mg tablets of fenoterol hydrobromide with 20-mg tablets of meta-proterenol for their ... Oral Therapy with Fenoterol Hydrobromide and Ephedrine Comparison. *Oral Therapy with Fenoterol Hydrobromide and Ephedrine ... Oral Therapy with Fenoterol Hydrobromide and Ephedrine Comparison Deliberations. Minette compared 6-mg and 12-mg tablets of ... Benjamin compared the effects of both 5-mg and 10-mg tablets of fenoterol with 40 mg of metaproterenol on the peak expiratory ...
These recommendations follow a review of available cardiovascular safety data on the medicines fenoterol, hexoprenaline, ... The medicines included in the EU review are: fenoterol, hexoprenaline, isoxsuprine, ritodrine, salbutamol and terbutaline, ...
Atosiban versus fenoterol as a uterine relaxant for external cephalic version: Randomised controlled trial. ... Dive into the research topics of Atosiban versus fenoterol as a uterine relaxant for external cephalic version: Randomised ...
During the extensive two-year review process for the 2021 version of the Code, WADA received considerable stakeholder feedback related to drugs of abuse where it was felt that the use of some substances included in the Prohibited List was often unrelated to sport practice. Accordingly, Article 4.2.3 was added to the 2021 Code defining Substances of Abuse as those "Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.". In this context, cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy") and tetrahydrocannabinol (THC) are designated as Substances of Abuse. These 4 substances are prohibited in competition but sometimes their use out-of-competition can be detected in-competition and lead to an Adverse Analytical Finding. If the athlete can demonstrate that the use of any of these four substances was out-of -competition and unrelated to sport ...
Clinical Trial 2013; 34(6): 553-558 PubMed PMID: 24378443 Citation Keywords: Adult, Female, Fenoterol:administration & dosage, ... Clinical Trial 2013; 34(6): 549-552 PubMed PMID: 24378442 Citation Keywords: Adult, Female, Fenoterol:administration & dosage, ... 48-hours administration of fenoterol in spontaneous preterm labor - does it affect fetal preload?. Grzesiak M, Forys S, Sobczak ... MATERIAL AND METHODS: Doppler evaluation of placental and fetal circulation was performed prior to fenoterol administration and ...
Fenoterol: The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol.. Fluoxetine: The SSRI, ...
Fenoterol hydrobromide+ipratropium bromide. Date of publication: 09/07/2014. *Fentanyl. Date of publication: 30/10/2015 ...
Fenoterol Hydrobromide Dosage: 2bt single dose Administration route: Oral Indication: Product Used FOR Unknown Indication Start ...
Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial BMJ 2017; 356 :i6773 ...
Fenoterol for peak identification CRS. Y0000779. Chlortalidone for peak identification CRS. Replaced by Y0002129 Chlortalidone ...
R03A L01 - Fenoterol og ipratropiumbromid. R03A L02 - Salbutamol og ipratropiumbromid. R03A L03 - Vilanterol og ...
Clinical Trial 2013; 34(6): 553-558 PubMed PMID: 24378443 Keywords: Adult, Female, Fenoterol:administration & dosage, Fetus: ... OBJECTIVES: The aims were to investigate whether any changes in placental and fetal circulation were observed during fenoterol ... Grzesiak M, Hincz P, Forys S, Ahmed R, Wilczynski J. 48-hours administration of fenoterol in spontaneous preterm labor - ... 48-hours administration of fenoterol in spontaneous preterm labor - Doppler blood flow assessment of placental and fetal ...
Metaproterenol (Alupent) is structurally similar to terbutaline (Brethaire) and fenoterol and is classified as a resorcinol ... Fenoterol (Berotec) is classified as a β2-adrenergic receptor agonist. * Following inhalation, rapid onset of action is ... Abnormal cardiac rhythms and other cardiac effects are likely mediated by fenoterol activity at myocardial β1-adrenergic ...
Athletes and fenoterol. Thorax 55 (2000) 441-442. Für eine optimale Darstellung dieser Seite aktivieren Sie bitte JavaScript. ...
Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. (1 February, 1991) Free J ...
Fenoterol *Levalbuterol hydrochloride (Xopenex) *Levalbuterol tartrate (Xopenex HFA) *Pirbuterol (Maxair) There is no evidence ...
Fenoterol infusion only intended for repression of labour is classified in G02CA. Combinations with xanthines are classified in ...
Tagged asalbuterolasthmabeta agonistsfenoterolheart failureinhalerssafetytheophyllineWhat Doctors Dont Tell You ... or one of the beta-agonists such as albuterol and fenoterol. But those who take their medication by metered dose inhalers have ...
decreased effectiveness of short-acting, inhaled bronchodilators such as salbutamol, terbutaline, or fenoterol (less than 4 ...
Like inhaled fenoterol, oral beta-agonists, theophylline, cromolyn, inhaled steroids, and oral steroids were all associated ...
Per puff of Berodual MDI Ipratropium Br 0.02 mg, fenoterol HBr 0.05 mg. Per mL Berodual soln Ipratropium Br 0.25 mg, fenoterol ... Berodual Respimat metered-dose Inhaler Per puff of Berodual MDI Ipratropium Br 0.02 mg, fenoterol HBr 0.05 mg 200 Puff/10 mL x ... Berodual Respimat metered-dose Inhaler Per puff of Berodual MDI Ipratropium Br 0.02 mg, fenoterol HBr 0.05 mg 200 Puff/10 mL x ... Berodual Inhalation Solution aka Berodual Inhaler Per mL Berodual soln Ipratropium Br 0.25 mg, fenoterol HBr 0.5 mg Inhalation ...
Fenoterol for system suitability (Y0002102) CRS batch 1 is shipped on Ice+5°C (previously at ambient temperature). ...
Response of asthmatic patients to fenoterol inhalation: a method of quantifying the airway bronchodilator dose. Clin Pharmacol ...
A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with ...
The β-agonists, procaterol, clenbuterol, fenoterol and terbutaline, inhibited TNF-α and IL-1β production in a concentration- ...
... had a 13 times higher risk of dying when using Fenoterol (Crane J, Pearce N et al: Prescribed fenoterol and death from asthma ... This figure was drastically reduced when in 1991 the inhaler drug Fenoterol was banned. Belatedly it was found that patients ...
建立一個適合使用呼吸器病人最舒適的住院環境
Fenoterol-induced Erythema Exudativum Multiforme-like Exanthem: Demonstration of Drug-specific Lymphocyte Reactivity In Vivo ...
  • About 25 mcg ipratropium bromide and 50 mcg fenoterol HBr per kg body weight per dose up to 0.5 mL (10 drops) up to 3 times daily. (1meds.com)
  • R03AL01 - fenoterol and ipratropium bromide : Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. (azurewebsites.net)
  • Minette compared 6-mg and 12-mg tablets of fenoterol hydrobromide with 20-mg tablets of meta-proterenol for their bronchodilator efficacy, as measured by changes in FEV1. (onlineasthmainhalers.com)
  • Only two of the 20 patients in our study developed nervousness after receiving the 5-mg dose of fenoterol hydrobromide, while three patients experienced this complaint after receiving the 7.5-mg dose, as well as after the 10-mg dose. (onlineasthmainhalers.com)
  • The results of this study demonstrate that when given orally in doses of at least 5 mg, fenoterol hydrobromide is an effective bronchodilator drug. (onlineasthmainhalers.com)
  • Metaproterenol had a more rapid onset of action, but after one hour, both doses of fenoterol resulted in greater bronchodila-tion. (onlineasthmainhalers.com)
  • Benjamin compared the effects of both 5-mg and 10-mg tablets of fenoterol with 40 mg of metaproterenol on the peak expiratory flow in asthmatic patients. (onlineasthmainhalers.com)
  • Fenoterol has more cardiovascular toxicity than isoprenaline or salbutamol. (wikipedia.org)
  • In the same study, it was also shown that both of these doses of fenoterol resulted in greater and more prolonged bronchodilation than that produced by oral administration of 4 mg of albuterol (salbutamol). (onlineasthmainhalers.com)
  • We have achieved good separation of clenbuterol, salbutamol, terbutaline and fenoterol with good resolution and reasonable retention times using a high concentration of methanol modifier in the supercritical CO 2 , together with small amounts of both acidic (trifluroacetic acid, TFAA) and basic (triethylamine, TEA, or diethylamine, DEA) additives. (nottingham.edu.cn)
  • Single ion monitoring (SIM) gave detection limits (on-column) of 2.5 ng (clenbuterol), 0.83 ng (terbutaline), 7.6 ng (salbutamol) and 2.7 ng (fenoterol). (nottingham.edu.cn)
  • The death rate from heart failure was greatest among those taking theophylline, or one of the beta-agonists such as albuterol and fenoterol. (healthy.net)
  • Like inhaled fenoterol, oral beta-agonists, theophylline, cromolyn, inhaled steroids, and oral steroids were all associated with an increased risk of SLTA. (nih.gov)
  • fenoterol was found to have a greater and more prolonged bronchodilator effect. (onlineasthmainhalers.com)
  • In an extensive review of -sympathomimetic drugs used in the treatment of asthma, Leifer and Wittig claimed that the available literature makes fenoterol "appear to be the bronchodilator of choice in the world. (onlineasthmainhalers.com)
  • Although the present study does not provide grounds for such an enthusiastic claim, it is clear that fenoterol must be considered to be a bronchodilator drug of major importance. (onlineasthmainhalers.com)
  • We conclude from this study that fenoterol is a valuable bronchodilator drug, effective for up to eight hours after administration when given orally. (onlineasthmainhalers.com)
  • No significant cardiac side effects were noted with these higher doses of fenoterol, indicating that this drug is a relatively selective stimulator of /fe-adrenergic receptors. (onlineasthmainhalers.com)
  • In a study of ten coal miners selected for the presence of reversible bronchial obstruction, Minette compared 12mg tablets of fenoterol with 2-mg tablets of albuterol and with placebo tablets. (onlineasthmainhalers.com)
  • Fenoterol is produced and sold by Boehringer Ingelheim as Berotec N and in combination with ipratropium as Berodual N. It was patented in 1962 and came into medical use in 1971 but, in the 1980s, concerns emerged about its safety and its use being associated with an increased risk of death (see below). (wikipedia.org)
  • Per puff of Berodual MDI Ipratropium Br 0.02 mg, fenoterol HBr 0.05 mg. (1meds.com)
  • Per mL Berodual soln Ipratropium Br 0.25 mg, fenoterol HBr 0.5 mg. (1meds.com)
  • Fenoterol was widely used in New Zealand in the late 1970s and the 1980s until it was removed from the New Zealand drug tariff in 1989 because its introduction and widespread use was associated with an epidemic of asthma deaths. (wikipedia.org)
  • The mortality rate declined following withdrawal of fenoterol without evidence supporting an alternative explanation for the abrupt rise and fall in asthma deaths. (wikipedia.org)
  • Since the onset of action of fenoterol is delayed, with peak effects occurring from two to three hours after administration, its role in the treatment of asthma and other bronchospastic diseases will largely be in the prevention of exacerbations and in long-term maintenance therapy, rather than in the treatment of acute episodes. (onlineasthmainhalers.com)
  • Belatedly it was found that patients with the most severe asthma (defined by a hospital admission during the previous year and prescription of oral corticosteroids) had a 13 times higher risk of dying when using Fenoterol (Crane J, Pearce N et al: Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. (health-science-spirit.com)
  • Increases in this measurement were greater and more prolonged for the fenoterol-treated patients. (onlineasthmainhalers.com)
  • Insignificant side effects were reported following the administration of fenoterol. (onlineasthmainhalers.com)
  • 48-hours administration of fenoterol in spontaneous preterm labor - Doppler blood flow assessment of placental and fetal circulation. (nel.edu)
  • Grzesiak M, Hincz P, Forys S, Ahmed R, Wilczynski J. 48-hours administration of fenoterol in spontaneous preterm labor - Doppler blood flow assessment of placental and fetal circulation. (nel.edu)
  • No other significant subjective or objective adverse effects were detected following any of the three dosages of fenoterol. (onlineasthmainhalers.com)
  • Fenoterol is a β adrenoreceptor agonist. (wikipedia.org)
  • Fenoterol is a short-acting β2 agonist that also stimulates β1 receptors. (wikipedia.org)
  • The pharmacokinetic and bioavailability of fenoterol, a B2 adrenergic agonist were studied to determine the feasibility of enhanced transdermal delivery. (uri.edu)
  • 12. Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding. (nih.gov)
  • 19. Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor. (nih.gov)
  • In this study, we examined the effects of the β 2 -adrenoceptor agonist, fenoterol, on the expression of H 1 receptors at the mRNA and protein levels, and functional responses. (aspetjournals.org)
  • Experiments were conducted to determine whether the β 2 -AR agonist ( R,R ′)-fenoterol and other β 2 -AR agonists could attenuate mitogenesis and, if so, by what mechanism. (aspetjournals.org)
  • In rats, the age-related decrease in the maximal rate of relaxation is reversed after 4-wk administration with the β 2 -adrenoceptor agonist (β 2 -agonist) fenoterol. (mcmaster.ca)
  • Comparative molecular field analysis of fenoterol derivatives: a platform towards highly selective and effective β2-adrenergic receptor agonists. (sri.com)
  • 3. Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. (nih.gov)
  • 6. Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition. (nih.gov)
  • 9. Molecular interactions between fenoterol stereoisomers and derivatives and the β₂-adrenergic receptor binding site studied by docking and molecular dynamics simulations. (nih.gov)
  • 17. Quantitative determination of fenoterol and fenoterol derivatives in rat plasma using on-line immunoextraction and liquid chromatography/mass spectrometry. (nih.gov)
  • Thus, fenoterol increases the expression of airway smooth muscle H 1 receptors via activation of the cAMP system through increased gene transcription and mRNA stability. (aspetjournals.org)
  • the first was a liquid formulation of fenoterol in Transcutol: Oleic acid in a ratio 1:1(F1), while the second was a matrix system of fenoterol in Duro-tak® 87-2074 adhesive with 10% 1-dodecyl-2-pyrrolidinone as an enhancer (F2). (uri.edu)
  • For comparison, control matrix with fenoterol without any enhancer (F3) was also tested. (uri.edu)
  • In the RG, fenoterol administration reversed an age-related selective nitration of the SERCA2a isoform. (mcmaster.ca)
  • Fenoterol was widely used in New Zealand in the late 1970s and the 1980s until it was removed from the New Zealand drug tariff in 1989 because its introduction and widespread use was associated with an epidemic of asthma deaths. (wikipedia.org)
  • Fenoterol has been widely used to treat asthmatic patients. (uri.edu)
  • Toxic injury of hepatic cells being suspected, fenoterol therapy was withdrawn, followed by a decrease of aminotransferases activity to normal values in those five (5) cases. (nih.gov)
  • Since no other hepatotoxic factors appeared, it may be assumed that a chronic administration of fenoterol can cause transient injuries of hepatic cells. (nih.gov)
  • R,R ′)-fenoterol and other β 2 -AR agonists, as well as forskolin, stimulated cAMP accumulation in a dose-dependent manner. (aspetjournals.org)
  • Hypokalaemia in pregnant women treated with the beta 2-mimetic drug fenoterol--a concentration and time dependent effect. (nih.gov)
  • The results showed a maximum concentration of fenoterol in plasma of 514.8 ng/ml after application of the liquid formula while its AUC 0-∞ amounted to be 485972(ng*min/ml) with a dose of 3mg/kg. (uri.edu)
  • In the contraction experiments, the concentration-response curves for histamine-induced contraction were shifted significantly to the left after 18-h exposure to fenoterol, consistent with the increase in receptor number. (aspetjournals.org)
  • The fenoterol-induced increase in H 1 receptor mRNA was concentration-dependent and was abolished by propranolol and ICI 118551, but not by CGP 20712A, indicating that fenoterol acts via β 2 -adrenoceptors. (aspetjournals.org)
  • 11. Chiral separation of the β2-sympathomimetic fenoterol by HPLC and capillary zone electrophoresis for pharmacokinetic studies. (nih.gov)
  • Our findings demonstrate that the mechanisms underlying age-related changes in contractile properties are fiber type dependent, whereas the effects of fenoterol administration are independent of age and fiber type. (mcmaster.ca)
  • Given the critical role of the sarcoplasmic reticulum (SR) in regulating intracellular Ca 2+ transients and ultimately the time course of muscle contraction and relaxation, we tested the hypothesis that the mechanisms of action of fenoterol are mediated by alterations in SR proteins. (mcmaster.ca)
  • 5. The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta(2)-adrenoceptor. (nih.gov)
  • 8. Stereochemical and conformational study on fenoterol by ECD spectroscopy and TD-DFT calculations. (nih.gov)
  • In five (5) cases a significant rise of ALAT and AspAT aminotransferase activity occurred during fenoterol therapy. (nih.gov)
  • UDPGT activity towards fenoterol is restricted to the liver and intestine and is not induced by PB, 3MC or A1254. (nih.gov)
  • Blood samples were collected via auricle central vein for 24 hours and the plasma concentrations of fenoterol were determined by LC-MS/MS method. (uri.edu)
  • 18. Development and validation of a sensitive LC-MS/MS method for the determination of fenoterol in human plasma and urine samples. (nih.gov)
  • Because a significant portion of brain tumors contain β 2 -ARs to a greater extent than whole brain, ( R,R ′)-fenoterol, or some analog, may be useful in the treatment of brain tumors after biopsy to determine β 2 -AR expression. (aspetjournals.org)
  • Fenoterol treatment increased the V max of SERCA and SERCA1 protein levels in RG and WG. (mcmaster.ca)
  • In addition, cells were incubated with ( R,R ′)-fenoterol and analogs to determine their ability to stimulate intracellular cAMP accumulation and inhibit [ 3 H]thymidine incorporation into the cells. (aspetjournals.org)
  • 15. Fenoterol enantiomers do not possess beneficial therapeutic properties of their racemic mixture in the rat model of post myocardial infarction dilated cardiomyopathy. (nih.gov)
  • Sarcoendoplasmic reticulum Ca 2+ -ATPase (SERCA) kinetic properties were assessed in muscle homogenates and enriched SR membranes isolated from the red (RG) and white (WG) portions of the gastrocnemius muscle in adult (16 mo) and aged (28 mo) F344 rats that had been administered fenoterol for 4 wk (1.4 mg/kg/day ip, in saline) or vehicle only. (mcmaster.ca)

No images available that match "fenoterol"